# Suven Life Sciences share price today (Suven Life Sciences Ltd, NSE: SUVEN)

> Suven Life Sciences share price today: ₹261.20 at the NSE close on 3 November 2026, up 32.2% in a year. Suven Life Sciences (NSE: SUVEN) is worth ₹7,376 crore, trades at a P/E of 2.6 and has closed between ₹130.19 and ₹378.00 over the past 52 weeks. > Suven Life Sciences Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SUVEN · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/suven-life-sciences-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹261.20 (+32.2% in a year)
- P/E: 2.6× (lower than 84% of the last 3 years)
- Revenue (Jun 2026): ₹4.0 Cr (+100.0% on a year ago)
- Profit (Jun 2026), incl. one-off: −₹128 Cr (one-off item, see below)
- ROCE: −80%, FY26
- Profit that came in as cash: 87%, last 3 years

Biggest thing to watch: the price has already been rising for 25 weeks, so timing is the risk more than the business. ## What is the Suven Life Sciences share price today? Suven Life Sciences Ltd's share price was ₹261.20 at the close on 3 November 2026. It has been rising for 25 weeks. That is 3.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹130 and ₹378, and at that close it sat 53% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 6 weeks running. Over the last 11 years the share price moved +1,941% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 28 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Suven Life Sciences this quarter? Three changes stood out: operating margin down 997 points on a year earlier, foreign funds (FIIs) cut their stake for 5 quarters in a row and indian funds and insurers (DIIs) cut their stake for 3 quarters in a row. 1. Operating margin down 997 points on a year earlier -3711% in the June 2026 quarter, from -2714%. 2. Foreign funds (FIIs) cut their stake for 5 quarters in a row From 1.2% to 0.5% of the company by the September 2026 quarter. 3. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row From 4.6% to 2.2% of the company by the September 2026 quarter. ## What are Suven Life Sciences' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Suven Life Sciences reported revenue of ₹4.00 crore, up 100.0% from ₹2.00 crore a year earlier, and a loss of ₹128 crore. ### Suven Life Sciences results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹4.00 crore | ₹2.00 crore | +100.0% |
| Profit | loss of ₹128 crore | loss of ₹52.0 crore | n/a |
| Earnings per share | ₹−4.83 | ₹−2.36 | n/a |
| Operating margin | −3,711.0% | −2,714.0% | −997.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Suven Life Sciences share price history? Suven Life Sciences closed at ₹261.20 on 3 November 2026, up 32.2% from ₹197.55 a year earlier (31 October 2025) and up 173.0% over five years. Its highest weekly close since March 2016 was ₹378.00 on 4 September 2026. ### Suven Life Sciences share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹261.35 | −0.1% |
| 1 month ago · 1 Oct 2026 | ₹308.30 | −15.3% |
| 6 months ago · 30 Apr 2026 | ₹211.88 | +23.3% |
| 1 year ago · 31 Oct 2025 | ₹197.55 | +32.2% |
| 3 years ago · 3 Nov 2023 | ₹77.95 | +235.1% |
| 5 years ago · 4 Nov 2021 | ₹95.67 | +173.0% |
| 10 years ago · 4 Nov 2016 | ₹11.10 | +2,253.2% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹12.80 | +1,940.6% |
| Highest weekly close since March 2016, also the 52-week high · 4 Sep 2026 | ₹378.00 | −30.9% |
| Lowest weekly close since March 2016 · 11 Aug 2017 | ₹9.93 | +2,530.4% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹130.19 | +100.6% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Suven Life Sciences? 3 Nov 2026: Suven Life Sciences closed at ₹261.20, down 0.1% on the week and down 15.3% on the month. Results for April to June 2026: Revenue up 100.0% on a year earlier. ## What dividend does Suven Life Sciences pay? Suven Life Sciences has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. Not in its latest year. Suven Life Sciences Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 5 of its last 13 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Suven Life Sciences on? Suven Life Sciences is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 7678.499130770715](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Suven Life Sciences profitable? Suven Life Sciences Ltd posted a net loss of ₹128 Cr in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY26 year was a loss of ₹276 Cr. That loss is 3,200.0% of the quarter's revenue. The same quarter a year earlier lost ₹52.0 Cr. 12 of the last 12 reported quarters were loss-making. Read this profit with care: at −₹128 Cr it is bigger than the quarter's whole revenue of ₹4.0 Cr. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −3,711.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Suven Life Sciences make, and is it growing? Suven Life Sciences Ltd reported ₹4.0 Cr of revenue in the Jun 2026 quarter, +100.0% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 10 years it has grown −34.7% a year on average. The last full year, FY26, came in at ₹7.0 Cr. The last four reported quarters add to ₹10.0 Cr. FY26 revenue was ₹7.0 Cr, +0.0% on the year before. Recent pace: the last four quarters grew +45.8% on average, against −34.7% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +25.0%, against +11.8% a year over the last 8 quarters (accelerating). ## How much of every ₹100 of sales does Suven Life Sciences keep? Suven Life Sciences Ltd's sales have fallen to very little: FY26 revenue was ₹7.0 Cr, against ₹625 Cr in FY18. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is Suven Life Sciences' profit turning into cash? Over the last 3 years, 87% of Suven Life Sciences Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 its operations used ₹300 Cr of cash, against −₹276 Cr of profit. After ₹23.0 Cr of spending on assets, free cash was −₹323 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Suven Life Sciences' cash go? Suven Life Sciences Ltd's customer, stock and supplier day counts are not a useful reading on sales this small (₹7.0 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹58.0 Cr on assets over the last 3 years. Averaged over those years that is 276.2% of FY26 revenue a year. Spending on assets: ₹58.0 Cr over the last 3 years, against ₹18.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹4.0 Cr (FY26): assets paid for that are not earning yet. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Suven Life Sciences' P/E ratio, and how does it compare with its own history? Suven Life Sciences Ltd's P/E is 2.6×, near the low end of its own history: it has been lower only 16% of the time. Its usual P/E (the middle reading) is 3.2×, over 3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 3 years the price moved +49.6% a year; about +23.4% a year came from earnings growth and about +26.2 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Suven Life Sciences business getting better or worse? Suven Life Sciences Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Suven Life Sciences earn on its capital? Suven Life Sciences Ltd earned a ROCE of −80% in FY26. That is up from a low of −118% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −440%, a number that says nothing useful about the business. ## Does Suven Life Sciences have too much debt? Suven Life Sciences Ltd has total debt of ₹17.0 Cr against shareholder equity of ₹591 Cr as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.03 in FY22 to 0.03 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Suven Life Sciences shareholding pattern? Promoters cut their stake in Suven Life Sciences Ltd by 4.8 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 65.5% of the company. Domestic institutions moved +1.1 points over the same period, to 2.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −4.8 points over 8 quarters, to 65.5%; Domestic institutions: +1.1 points over 8 quarters, to 2.2%; Foreign institutions: +0.1 points over 8 quarters, to 0.5%. Why the owners changed: promoters drove it (−4.8 points), with the other side taken by domestic institutions (+1.1 points). They reduced their stake. ## How far is Suven Life Sciences from balance-sheet trouble? For Suven Life Sciences Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Suven Life Sciences rank in its industry? 33.1 out of 100, rank 40 of 44 in Pharma - Formulators, with 64% of the evidence available. Suven Life Sciences Ltd scores 33.1 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 40. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 13.3 + 2.1 + 10 + 7.7 = 33.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Suven Life Sciences compared with? Suven Life Sciences ranks 40 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 33.1 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. Suven Life Sciences Ltd this page SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.3/35 · Revenue 25% · Profit -80% · Operating margin change -997 points · 65% evidence Capital efficiency 2.1/25 · ROCE -79.5% · Operating margin n/a · 84% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 7.7/20 · Lead over its industry -3.9% · Lead over NIFTY 500 16.2% · 1 year 31% · 100% evidence · 7 of 12 weeks ahead Exact sum: 13.3 + 2.1 + 10 + 7.7 = 33.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Suven Life Sciences in size? Suven Life Sciences is the 26th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Corona Remedies, Akums Drugs & Pharmaceuticals and Strides Pharma Science. Just below it: Bliss GVS Pharma, FDC and RPG Life Sciences. ### Pharma - Formulators companies close in size

1. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) ₹13,147 crore
2. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) ₹11,517 crore
3. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) ₹9,851 crore
4. Suven Life Sciences Ltd ₹7,314 crore
5. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) ₹6,888 crore
6. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) ₹6,138 crore
7. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) ₹4,260 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Raymond Ltd](https://www.sectoralpha.in/stocks/raymond-ltd) ₹7,324 crore · Realty - Construction & Contracting
2. [Religare Enterprises Ltd](https://www.sectoralpha.in/stocks/religare-enterprises-ltd) ₹7,321 crore · Finance - Insurance
3. Suven Life Sciences Ltd ₹7,314 crore
4. [Vesuvius India Ltd](https://www.sectoralpha.in/stocks/vesuvius-india-ltd) ₹7,314 crore · Refractories
5. [Tourism Finance Corporation of India Ltd](https://www.sectoralpha.in/stocks/tourism-finance-corporation-of-india-ltd) ₹7,311 crore · Finance - PSU Lending

## What else do people ask about Suven Life Sciences? ### What is Suven Life Sciences's share price today? Suven Life Sciences Ltd's share price is ₹261.20, +32.2% over the past year. The whole company is worth ₹7,376 Cr on the market. In the last 52 weeks it traded between ₹130 to ₹378; today it is 53% of the way up from the low, 3.3% below its 200-day average (as of 3 November 2026). ### What were Suven Life Sciences's latest quarterly results? Suven Life Sciences Ltd reported revenue of ₹4.0 Cr and a net loss of ₹128 Cr for the Jun 2026 quarter. Earnings per share were −₹4.83. The operating margin was −3,711.0%, 997.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Suven Life Sciences's market cap? Suven Life Sciences Ltd's market capitalisation is ₹7,376 Cr at a share price of ₹261.20. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Suven Life Sciences performing? Suven Life Sciences Ltd's share price has been rising for 25 weeks. Over the past 13 weeks it has done worse than the NIFTY 500, for 6 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Suven Life Sciences's share price go up? This page does not forecast Suven Life Sciences Ltd's share price. What it shows instead: the share price is ₹261.20, and it has been rising for 25 weeks. Its P/E of 2.6× is higher than 16% of its own last 3 years (as of 3 November 2026). ### Who owns Suven Life Sciences? Promoters own 65.5% of Suven Life Sciences Ltd, foreign institutions 0.5%, domestic institutions 2.2% and the public 31.9% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 4.8 percentage points over 8 quarters (as of 3 November 2026). ### Does Suven Life Sciences have too much debt? No, Suven Life Sciences Ltd has little debt: its debt is 0.03× its equity, and its operating profit is −122 times its interest bill. FY26 borrowings were ₹17.0 Cr against equity of ₹591 Cr. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### What could break the Suven Life Sciences story? Biggest thing to watch: the price has already been rising for 25 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Suven Life Sciences a stock worth studying right now? What the numbers show: Suven Life Sciences Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.